Myomo Q2 Earnings Call Highlights
Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.
How this was made
The 30-second read
Why it matters
For traders, the key decision inputs are the raised full-year revenue range, Q3 revenue guidance, gross margin expansion, and the company’s stated plan to keep 2026 operating-expense growth at half the revenue growth rate while limiting H2 cash burn.
Market read
Raised revenue outlook and improved gross margin are the primary catalysts, while cash burn and clinical milestones remain key swing factors for valuation.
What to watch
Referral-sourced pipeline mix shift toward Medicare Part B could be beneficial, but investors may scrutinize sustainability of authorization rates, clinical trial enrollment pace, and the magnitude of cash burn versus the stated < $2M H2 target.
Background
The piece summarizes Myomo’s Q2 earnings call, focusing on pipeline/referral mix, margin drivers, reimbursement updates, clinical trial progress, and updated revenue outlook.
Ticker impact
Myomo raised its full-year revenue outlook to $45M-$47M and guided Q3 revenue to $11.5M-$12M after Q2 margin and pipeline improvements.
Likely positive bias for MYO around the earnings release, with follow-through dependent on whether investors focus on raised revenue outlook versus cash burn and clinical timelines.
The article discloses specific Q3 and full-year revenue ranges, gross margin expansion to 72.1%, and cash burn expectations for H2, which are direct inputs to valuation and near-term positioning.
Market effects
Signals improving reimbursement traction and gross margin expansion for medical robotics/assistive devices, potentially supportive for the small-cap medtech sentiment backdrop.
Limited direct regional spillover; most drivers are US reimbursement and Medicare Part B dynamics.
Germany market prototype and trial publication timeline are incremental, but the financial guidance is US-focused.
Counterpoint
Cash and derivative mark-to-market items plus ongoing operating loss mean the guidance upgrade may not fully de-risk dilution or funding needs.
Key entities
- companyMyomo
Medical robotics company (NYSE American: MYO) providing powered orthotic devices, with MyoConnect referral program and MyoPro product roadmap.
- programMyoConnect
Referral program whose share of pipeline additions increased to 17% in Q2 from 11% in Q1.
- productMyoPro 3
Next-generation device described as remaining on schedule, with a hand-only prototype shown for Germany.
- clinical_trialUniversity of Utah randomized controlled trial
Ongoing RCT with 25 of 50 planned patients enrolled, with updated 6-month outcomes expected in H2 2026.
